<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Platelet-rich arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> are resistant to lysis by plasminogen activators </plain></SENT>
<SENT sid="1" pm="."><plain>However, the mechanisms underlying thrombolysis resistance are poorly defined </plain></SENT>
<SENT sid="2" pm="."><plain>Plasminogen activator inhibitor-1 (PAI-1), which is present in plasma, platelets, and vascular endothelium, may be an important determinant of the resistance of arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> to lysis </plain></SENT>
<SENT sid="3" pm="."><plain>However, in vitro studies examining the regulation of platelet-rich clot lysis by PAI-1 have yielded inconsistent results </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND RESULTS: We developed a murine arterial injury model and applied it to <z:mp ids='MP_0002169'>wild-type</z:mp> (PAI-1 [+/+]) and PAI-1-deficient (PAI-1 [-/-]) animals </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="30808">FeCl3</z:chebi> was used to induce carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">Thrombi</z:e> consisted predominantly of dense platelet aggregates, consistent with the histology of <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in large-animal arterial injury models and human <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndromes </plain></SENT>
<SENT sid="7" pm="."><plain>To examine the role of PAI-1 in regulating endogenous clearance of platelet-rich arterial <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e>, <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were induced in 22 PAI-1 (+/+) mice 14 PAI-1 (-/-) mice </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty-four hours later, the amount of residual <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was determined by histological analysis of multiple transverse sections of each artery </plain></SENT>
<SENT sid="9" pm="."><plain>Residual <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was detected in 55 of 85 sections (64.7%) obtained from PAI-1 (+/+) mice compared with 19 of 56 sections (33.9%) from PAI-1 (-/-) mice (P=.009) </plain></SENT>
<SENT sid="10" pm="."><plain>Computer-assisted planimetry analysis revealed that mean <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> cross-sectional area was 0.033+/-0.0271 mm2 in PAI-1 (+/+) mice versus 0.016+/-0.015 mm2 in PAI-1 (-/-) mice (P=.048) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: PAI-1 is an important determinant of thrombolysis at sites of arterial injury </plain></SENT>
<SENT sid="12" pm="."><plain>Application of this model to other genetically altered mice should prove useful for studying the molecular determinants of <z:hpo ids='HP_0004420'>arterial thrombosis</z:hpo> and thrombolysis </plain></SENT>
</text></document>